Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors
- PMID: 8348562
- PMCID: PMC11038831
- DOI: 10.1007/BF01518516
Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors
Abstract
In the present study we demonstrate the ability of allogeneic M3 tumor cells to induce an antitumor response against the syngeneic tumor, when injected locally together with syngeneic B16 melanoma cells. The replacement of the allogeneic tumor cells with either syngeneic or allogeneic splenocytes had no effect on the growth of the syngeneic tumor. Systemic administration of both interleukin-2 (IL-2) and IL-6 did not affect the antitumor response induced by allogeneic tumor cells. When mice, previously injected with B16 and M3 cells, were rechallenged subcutaneously with B16 tumor cells at a different anatomical site, an inhibitory effect in some, but not all, experiments was observed. Systemic injections of either IL-2 or IL-6 did not alter the antitumor effects of the allogeneic and syngeneic tumor-cell mixtures. The significance of our results in developing immunotherapy modalities based on active immunization with allogeneic tumor cells and selected cytokines is discussed.
Similar articles
-
Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.Cancer Res. 1997 Aug 1;57(15):3230-7. Cancer Res. 1997. PMID: 9242454
-
Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.Cancer Gene Ther. 2000 Jun;7(6):870-8. doi: 10.1038/sj.cgt.7700183. Cancer Gene Ther. 2000. PMID: 10880017
-
Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.Neurosurgery. 1997 Oct;41(4):898-906; discussion 906-7. doi: 10.1097/00006123-199710000-00025. Neurosurgery. 1997. PMID: 9316052
-
The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.Cancer Immunol Immunother. 2006 Mar;55(3):277-88. doi: 10.1007/s00262-005-0061-2. Epub 2005 Sep 13. Cancer Immunol Immunother. 2006. PMID: 16158275 Free PMC article.
-
Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.Int J Cancer. 1993 Nov 11;55(5):865-72. doi: 10.1002/ijc.2910550528. Int J Cancer. 1993. PMID: 8244584
References
-
- Belldegrun A, Webb DE, Howard AA, Steinberg AM, Linehan WM, Rosenberg SA. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pretherapy nephrectomy. J Urol. 1989;141:499. - PubMed
-
- Eisenthal A, Rosenberg SA. Systemic induction of ADCC following administration of interleukin-2. Cancer Res. 1989;49:6953. - PubMed
-
- Eisenthal A, Rosenberg SA. The effect of various cytokines on the in vitro induction of ADCC in murine cells: enhancement of the IL-2 induced ADCC activity by IL-1. J Immunol. 1989;142:2307. - PubMed
-
- Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA. The effect of anti B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res. 1987;47:2771. - PubMed
-
- Eisenthal A, Shiloni E, Rosenberg SA. Characterization of interleukin-2 induced murine cells which exhibit ADCC activity. Cell Immunol. 1988;115:257. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources